PaxMedica, Common Stock Performance
| PXMDDelisted Stock | USD 0.86 0.18 17.31% |
The company holds a Beta of 0.11, which implies not very significant fluctuations relative to the market. As returns on the market increase, PaxMedica, Common's returns are expected to increase less than the market. However, during the bear market, the loss of holding PaxMedica, Common is expected to be smaller as well. PaxMedica, Common Stock right now holds a risk of 0.0%. Please check PaxMedica, Common Stock potential upside, daily balance of power, as well as the relationship between the Daily Balance Of Power and market facilitation index , to decide if PaxMedica, Common Stock will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PaxMedica, Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, PaxMedica, Common is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 1.9 M |
PaxMedica, |
PaxMedica, Common Relative Risk vs. Return Landscape
If you would invest 86.00 in PaxMedica, Common Stock on September 4, 2024 and sell it today you would earn a total of 0.00 from holding PaxMedica, Common Stock or generate 0.0% return on investment over 90 days. PaxMedica, Common Stock is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than PaxMedica,, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PaxMedica, Common Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PaxMedica, Common's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as PaxMedica, Common Stock, and traders can use it to determine the average amount a PaxMedica, Common's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PXMD |
Based on monthly moving average PaxMedica, Common is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PaxMedica, Common by adding PaxMedica, Common to a well-diversified portfolio.
PaxMedica, Common Fundamentals Growth
PaxMedica, Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of PaxMedica, Common, and PaxMedica, Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PaxMedica, Pink Sheet performance.
| Return On Equity | -10.47 | ||||
| Return On Asset | -2.56 | ||||
| Current Valuation | 388.33 K | ||||
| Shares Outstanding | 7.47 M | ||||
| Price To Earning | 1.90 X | ||||
| Price To Book | 1.83 X | ||||
| EBITDA | (16.15 M) | ||||
| Cash And Equivalents | 9.06 K | ||||
| Total Debt | 173.54 K | ||||
| Debt To Equity | 0.07 % | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (10.77 M) | ||||
| Earnings Per Share | (11.00) X | ||||
| Total Asset | 5.68 M | ||||
| Retained Earnings | (52.03 M) | ||||
About PaxMedica, Common Performance
By analyzing PaxMedica, Common's fundamental ratios, stakeholders can gain valuable insights into PaxMedica, Common's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PaxMedica, Common has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PaxMedica, Common has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC. Paxmedica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.Things to note about PaxMedica, Common Stock performance evaluation
Checking the ongoing alerts about PaxMedica, Common for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for PaxMedica, Common Stock help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PaxMedica, Common is not yet fully synchronised with the market data | |
| PaxMedica, Common has some characteristics of a very speculative penny stock | |
| PaxMedica, Common has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (18.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PaxMedica, Common Stock currently holds about 9.06 K in cash with (10.77 M) of positive cash flow from operations. |
- Analyzing PaxMedica, Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PaxMedica, Common's stock is overvalued or undervalued compared to its peers.
- Examining PaxMedica, Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PaxMedica, Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PaxMedica, Common's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PaxMedica, Common's pink sheet. These opinions can provide insight into PaxMedica, Common's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in PaxMedica, Pink Sheet
If you are still planning to invest in PaxMedica, Common Stock check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PaxMedica, Common's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |